- Conditions
- Covid19
- Interventions
- hMSC
- Biological
- Lead sponsor
- Stemedica Cell Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Fullerton, California • Santa Monica, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 390
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
- Conditions
- Prostate Cancer
- Interventions
- enzastaurin, placebo, docetaxel, prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 22
- States / cities
- Fullerton, California • Los Angeles, California • Northridge, California + 19 more
- Conditions
- Acute Ischemic Stroke
- Interventions
- Argatroban, Eptifibatide, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Interventions
- Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Pembrolizumab, Veliparib
- Drug · Radiation · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 645
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- cilomilast
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 103 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 989
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 16
- States / cities
- Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more
- Conditions
- High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
- Interventions
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
- Drug
- Lead sponsor
- Aadi Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Fullerton, California • Newport Beach, California • Santa Monica, California
- Conditions
- Hypogonadism, Cardiovascular Diseases
- Interventions
- AndroGel®, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 5,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 379
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
- Interventions
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 174
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
- Interventions
- Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 739 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 709
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 53 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Adalimumab, Methotrexate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more
- Conditions
- Cancer
- Interventions
- Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 39
- States / cities
- Tucson, Arizona • Bakersfield, California • Fullerton, California + 35 more
- Conditions
- Stroke, Ischemic
- Interventions
- Penumbra System
- Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 29
- States / cities
- Mesa, Arizona • Castro Valley, California • Fullerton, California + 25 more
- Conditions
- COVID-19 Pneumonia
- Interventions
- Tociliuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 70
- States / cities
- Beverly Hills, California • Fountain Valley, California • Fullerton, California + 58 more
- Conditions
- Atrial Fibrillation
- Interventions
- dabigatran dose 1, dabigatran dose 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,897 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Lake Havasu City, Arizona + 185 more
- Conditions
- Melanoma
- Interventions
- fianlimab, cemiplimab, relatlimab+nivolumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 106
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Standard of care
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 180
- States / cities
- Buena Park, California • Burbank, California • Costa Mesa, California + 144 more
- Conditions
- Cytokine Storm (Covid-19)
- Interventions
- Ruxolitinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 11
- States / cities
- Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more
- Conditions
- Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Guardant Health, Inc.
- Industry
- Eligibility
- 45 Years to 84 Years
- Enrollment
- 44,467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 271
- States / cities
- Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more